Q-omics provides the consensus-scored MIR3117 profile across patient tissues and cancer cell-line models. MIR3117 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR3117 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, MIR3117 RNA expression shows 12,164 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRP, and LSCC as cancer lineages where MIR3117 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3117 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3117 survival associations across molecular data types. MIR3117 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3117 RNA expression–survival associations across cancer types. High MIR3117 expression shows unfavorable associations in COAD, THYM, STAD, CESC and ACC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR3117 RNA expression.
This table summarizes MIR3117 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3117. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3117 shows lower tumor expression in KIRP, LUAD, KIRC, THCA, LUSC and KICH. The KIRP box plot shows higher MIR3117 RNA expression in normal versus tumor tissue (log2 FC = −0.850, t-test p < 0.001).
This table shows molecular features associated with MIR3117 in patient tissues and cancer cell lines. In patient samples, MIR3117 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
